玻璃体内注射地塞米松植入物对硅油填充下玻璃体切除术后黄斑水肿的单剂量效应

Single-dose Effect of Intravitreal Dexamethasone Implant for Post-vitrectomy Macular Edema under Silicone Oil.

作者信息

Hsu Cherng-Ru, Hsieh Yi-Ting, Yang Chung-May, Lin Chang-Ping

机构信息

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.

Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

出版信息

Ocul Immunol Inflamm. 2023 Oct;31(8):1587-1593. doi: 10.1080/09273948.2021.1970779. Epub 2021 Sep 3.

DOI:10.1080/09273948.2021.1970779

PMID:34477484

Abstract

PURPOSE

To investigate the single-dose effect of intravitreal dexamethasone (DEX) implant for patients with post-vitrectomy macular edema (ME) under silicone oil (SO) tamponade.

METHODS

Twelve eyes diagnosed with ME after undergoing pars plana vitrectomy with SO injections were retrospectively reviewed. Each eye received a single intravitreal DEX implant (0.7-mg, Ozurdex; Allergan Inc) injection as treatment for recalcitrant ME. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were recorded.

RESULTS

Compared with baseline (1.24 ± 0.34), the mean LogMAR BCVA improved at 1 (1.14 ± 0.27), 3 (1.13 ± 0.22), and 6 (1.22 ± 0.30) months without statistical significance. Maximal CMT resolution was observed at 1 month after intravitreal injection. The CMT value improved significantly at 1 ( = .008), 3 ( = .006), and 6 ( = .009) months. IOP did not show significant elevation during follow-up. No serious adverse events were observed.

CONCLUSION

Single-dose treatment of DEX implant may have benefit for recalcitrant post-vitrectomy ME under SO tamponade.

摘要

目的

研究玻璃体内注射地塞米松（DEX）植入物对硅油（SO）填充下玻璃体切除术后黄斑水肿（ME）患者的单剂量效应。

方法

回顾性分析12例接受玻璃体切除联合SO注射后诊断为ME的患者的眼部情况。每只眼睛接受一次玻璃体内DEX植入物（0.7毫克，Ozurdex；Allergan公司）注射，作为顽固性ME的治疗方法。记录最佳矫正视力（BCVA）、中心黄斑厚度（CMT）和眼压（IOP）。

结果

与基线（1.24±0.34）相比，平均LogMAR BCVA在1个月（1.14±0.27）、3个月（1.13±0.22）和6个月（1.22±0.30）时有所改善，但无统计学意义。玻璃体内注射后1个月观察到CMT最大程度的消退。CMT值在1个月（P =.008）、3个月（P =.006）和6个月（P =.009）时显著改善。随访期间IOP未出现显著升高。未观察到严重不良事件。